This document lists 50 publications by Dr. Gilbert Lefèvre from 1987 to 2008. The publications cover a range of topics including:
- Anti-Müllerian hormone and related monoclonal antibodies (publications 1-3)
- Pharmacokinetic studies of drugs like hirudin, artemether, and rivastigmine (publications 4-10, 23-25, 45-50)
- Drug interaction and safety studies of antimalarial and Alzheimer's drugs (publications 26-28, 30-33, 36, 38, 40, 41, 44)
- Pharmacokinetic studies of antimalarial drugs in specific populations like children and Africans (publications 29, 42, 43)
This document describes the discovery of potent and selective inhibitors of the enzyme MTH1 by researchers seeking to validate claims that MTH1 inhibition can selectively kill cancer cells. The researchers developed three structurally distinct series of MTH1 inhibitors with excellent potency and selectivity based on previous work identifying MTH1 as a target of TLR7 agonists. Crystal structures showed the inhibitors binding in a similar manner to the natural MTH1 substrate. However, testing of the inhibitors in cells did not elicit the cancer-specific lethal phenotype reported for other MTH1 inhibitors, questioning the proposed role of MTH1 in cancer cell survival.
This document discusses the role of kinase inhibitors, specifically tofacitinib, in the treatment of rheumatoid arthritis (RA). It begins with an overview of RA pathogenesis and the involvement of kinases like JAK. It then describes the JAK-STAT signaling pathway and how tofacitinib works as a JAK inhibitor to suppress cytokines driving RA. Clinical trials showed tofacitinib effectively reduced symptoms and joint damage in RA patients, including those refractory to biologics. Common side effects included infections while safety monitoring is needed for liver enzymes, lipids and risk of infection.
Biologcals basics and their uses in rheumatological disorders pptNilesh Jadhav
Biological therapies are proteins manufactured similarly to human molecules that target specific components of the immune system. They include monoclonal antibodies and fusion proteins that selectively target pro-inflammatory cytokines and molecules involved in immune cell activation and maturation. This results in better control of diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus. Examples of biological therapies approved by regulatory agencies include TNF-alpha inhibitors like infliximab and etanercept for rheumatoid arthritis, and rituximab for cancers. Biological therapies aim to modify disease courses, limit complications from conventional treatments, and provide options for treatment-refractory disease.
Lung cancer 2011 talk-for 17-10-2011-17-10-2011Cheng Luo
This document discusses metagenes obtained from genome-wide association studies (GWAS) of lung cancer and their potential use as prognostic and personalized treatment biomarkers. Specifically, it mentions:
1. MAGE family genes obtained from GWAS can serve as immunotherapy targets for lung cancer. Previous studies have found MAGE expression correlates with survival in lung cancer patients.
2. Ongoing clinical trials are investigating MAGE-A3 vaccines as adjuvant therapy for resected early-stage lung cancers that express MAGE-A3, with the goal of improving disease-free and overall survival. Phase II trials found trends towards improved outcomes with MAGE-A3 vaccination.
3. MAGE expression in lung cancers
Novel immunotherapies for rheumatoid arthritisNJayabalan
This document discusses novel immunotherapies for rheumatoid arthritis that have been approved by the FDA. It provides details on 6 categories of immunotherapies: B cell depletion therapy, T cell costimulation inhibition, anti-IL-6 therapy, anti-TNFα therapy, Janus kinase inhibitors, and biosimilars. For each category, it describes example drugs, their mechanisms of action, effects, and potential side effects and risks. Overall, the document suggests that improved understanding of RA immunopathogenesis has led to more personalized, effective, and cost-efficient treatment options.
38th FEBS Congress
Maxim L. Bychkov
Poster for abstract: "DR5-B – DR5-selective mutant variant of cytokine TRAIL overcomes resistance of cancer cells to TRAIL"
Abstract book, p. 595
This document discusses a study that tested whether combining nelfinavir and curcumin could increase the efficacy of docetaxel in treating castration-resistant prostate cancer. The study found that exposing castration-resistant prostate cancer cells to physiological concentrations of nelfinavir and curcumin significantly enhanced the cytotoxicity of low-dose docetaxel and induced apoptosis. Molecular studies showed this 3-drug combination more strongly suppressed the AKT survival pathway and induced ER stress pathways in cancer cells compared to normal cells. In mouse models, the 3-drug combination also significantly enhanced the antitumor effects of docetaxel compared to docetaxel alone. Therefore, combining nelfinav
This document describes cardiotoxicity observed in rodents and in rat and human-derived cardiomyocyte cell lines treated with nicotinamide phosphoribosyltransferase inhibitors (NAMPTi). Short-term administration of several NAMPTis to rodents resulted in sudden death and signs of congestive heart failure. Further studies demonstrated that NAMPTi-induced toxicity in rat and human cardiomyocyte cell lines was on-target and likely human-relevant. Co-administration of nicotinic acid partially mitigated toxicity in vitro but not consistently in vivo. Human-derived cardiomyocyte assays were useful for assessing cardiotoxicity of compounds prior to in vivo studies.
This document describes the discovery of potent and selective inhibitors of the enzyme MTH1 by researchers seeking to validate claims that MTH1 inhibition can selectively kill cancer cells. The researchers developed three structurally distinct series of MTH1 inhibitors with excellent potency and selectivity based on previous work identifying MTH1 as a target of TLR7 agonists. Crystal structures showed the inhibitors binding in a similar manner to the natural MTH1 substrate. However, testing of the inhibitors in cells did not elicit the cancer-specific lethal phenotype reported for other MTH1 inhibitors, questioning the proposed role of MTH1 in cancer cell survival.
This document discusses the role of kinase inhibitors, specifically tofacitinib, in the treatment of rheumatoid arthritis (RA). It begins with an overview of RA pathogenesis and the involvement of kinases like JAK. It then describes the JAK-STAT signaling pathway and how tofacitinib works as a JAK inhibitor to suppress cytokines driving RA. Clinical trials showed tofacitinib effectively reduced symptoms and joint damage in RA patients, including those refractory to biologics. Common side effects included infections while safety monitoring is needed for liver enzymes, lipids and risk of infection.
Biologcals basics and their uses in rheumatological disorders pptNilesh Jadhav
Biological therapies are proteins manufactured similarly to human molecules that target specific components of the immune system. They include monoclonal antibodies and fusion proteins that selectively target pro-inflammatory cytokines and molecules involved in immune cell activation and maturation. This results in better control of diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus. Examples of biological therapies approved by regulatory agencies include TNF-alpha inhibitors like infliximab and etanercept for rheumatoid arthritis, and rituximab for cancers. Biological therapies aim to modify disease courses, limit complications from conventional treatments, and provide options for treatment-refractory disease.
Lung cancer 2011 talk-for 17-10-2011-17-10-2011Cheng Luo
This document discusses metagenes obtained from genome-wide association studies (GWAS) of lung cancer and their potential use as prognostic and personalized treatment biomarkers. Specifically, it mentions:
1. MAGE family genes obtained from GWAS can serve as immunotherapy targets for lung cancer. Previous studies have found MAGE expression correlates with survival in lung cancer patients.
2. Ongoing clinical trials are investigating MAGE-A3 vaccines as adjuvant therapy for resected early-stage lung cancers that express MAGE-A3, with the goal of improving disease-free and overall survival. Phase II trials found trends towards improved outcomes with MAGE-A3 vaccination.
3. MAGE expression in lung cancers
Novel immunotherapies for rheumatoid arthritisNJayabalan
This document discusses novel immunotherapies for rheumatoid arthritis that have been approved by the FDA. It provides details on 6 categories of immunotherapies: B cell depletion therapy, T cell costimulation inhibition, anti-IL-6 therapy, anti-TNFα therapy, Janus kinase inhibitors, and biosimilars. For each category, it describes example drugs, their mechanisms of action, effects, and potential side effects and risks. Overall, the document suggests that improved understanding of RA immunopathogenesis has led to more personalized, effective, and cost-efficient treatment options.
38th FEBS Congress
Maxim L. Bychkov
Poster for abstract: "DR5-B – DR5-selective mutant variant of cytokine TRAIL overcomes resistance of cancer cells to TRAIL"
Abstract book, p. 595
This document discusses a study that tested whether combining nelfinavir and curcumin could increase the efficacy of docetaxel in treating castration-resistant prostate cancer. The study found that exposing castration-resistant prostate cancer cells to physiological concentrations of nelfinavir and curcumin significantly enhanced the cytotoxicity of low-dose docetaxel and induced apoptosis. Molecular studies showed this 3-drug combination more strongly suppressed the AKT survival pathway and induced ER stress pathways in cancer cells compared to normal cells. In mouse models, the 3-drug combination also significantly enhanced the antitumor effects of docetaxel compared to docetaxel alone. Therefore, combining nelfinav
This document describes cardiotoxicity observed in rodents and in rat and human-derived cardiomyocyte cell lines treated with nicotinamide phosphoribosyltransferase inhibitors (NAMPTi). Short-term administration of several NAMPTis to rodents resulted in sudden death and signs of congestive heart failure. Further studies demonstrated that NAMPTi-induced toxicity in rat and human cardiomyocyte cell lines was on-target and likely human-relevant. Co-administration of nicotinic acid partially mitigated toxicity in vitro but not consistently in vivo. Human-derived cardiomyocyte assays were useful for assessing cardiotoxicity of compounds prior to in vivo studies.
This document describes research to develop new treatments for human African trypanosomiasis (HAT) by optimizing inhibitors of Trypanosoma brucei N-myristoyltransferase (TbNMT). The initial lead compound 1 showed potent activity against TbNMT but poor brain penetration, limiting its efficacy in the later central nervous system stage of HAT. The researchers modified compound 1 to improve blood-brain barrier permeability and selectivity against human NMTs. Key modifications included reducing the compound's polar surface area, replacing the central aromatic ring with a flexible linker, and capping the sulfonamide group. This led to the discovery of compound 40, which demonstrated partial efficacy in a mouse model
This document summarizes a study evaluating the toxicity and efficacy of novel targeted polymalic acid conjugate nanoparticles for treating triple-negative breast cancer. The nanoparticles were designed to target the epidermal growth factor receptor and laminin-411, a tumor vascular protein. In vitro and in vivo assays were conducted to evaluate the biocompatibility and toxicity of the polymalic acid platform and nanoparticle conjugates at low and high doses, as well as their efficacy in reducing tumor growth in mouse models over multiple treatment regimens. Blood analysis after intravenous administration in mice found no side effects, supporting the safety and potential of these nanoparticles for future cancer treatment in patients.
This document discusses immunotherapy strategies for metastatic renal cell carcinoma (RCC), including cytokines like interleukin-2 (IL-2) and interferon-α (IFN-α). It finds that high-dose IL-2 produces durable responses in a small percentage of selected patients, while IFN-α provides a modest survival benefit. Combining cytokines with targeted therapies may improve outcomes compared to cytokine monotherapy. Biomarkers like carbonic anhydrase IX expression and histologic subtype may help predict which patients are most likely to benefit from IL-2 therapy. Ongoing research aims to better select patients for IL-2 and explore combination therapies and novel immunotherapies to optimize treatment of metastatic RCC.
Novel 1,3,4-Thiadiazole Linked Amide Derivatives of Pteridone: Synthesis and ...Ratnakaram Venkata Nadh
Cancer is a second leading cause of death after heart attack, in developing as well as undeveloped
countries. It is caused by unregulated growth and metastasis of the abnormal cancer cells.
Cancer can be cured by radiation, immunotherapy and chemotherapy, among them; chemotherapy is a
good treatment for cancer, in which chemotherapeutic drug is used. The anticancer activity of newly
synthesized compounds (13a-j) was carried out on four different types of human cancer cell lines like
MCF-7 (breast), A549 (lung), Colo-205 (colon) and A2780 (ovarian) by the MTT method, and compared
to etoposide used as a positive control. Among them, compound 13g with electron-withdrawing
(3,5-dinitro) group, exhibited more promising activity in all cell lines (MCF-7 = 0.10±0.076 μM, A549
= 0.17±0.039 μM, Colo-205= 0.13±0.022 μM and A2780 = 0.87±0.027μM). This compound may act
as lead drug in cancer chemotherapy. In future, this compound can be examined for clinical studies.
MED12 controls the response to multiple cancer drugs through regulation of TG...Anirudh Prahallad
This study used an RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex, as a determinant of response to ALK and EGFR inhibitors in lung cancer cell lines. The study found that suppressing MED12 expression resulted in resistance to these targeted therapies. MED12 was found to negatively regulate TGF-β receptor signaling through physical interaction, and its suppression activated TGF-β signaling. Activation of TGF-β signaling led to MEK/ERK pathway activation, which conferred resistance to MEK, BRAF, and other cancer drugs. Loss of MED12 also induced an EMT-like phenotype associated with chemotherapy resistance in other cancer types. Inhibiting TGF-β receptor signaling
This document discusses epigenetically mediated toxicity and provides three key points:
1. Epigenetic modulation represents an intricate intersection of pharmacology, toxicology, and genotoxicity. It involves complex and reversible modifications to DNA and histones that can be influenced by environmental and therapeutic factors.
2. Toxicities associated with epigenetic modulation include effects on reproductive, hematopoietic, and developmental systems. However, there is no unique pattern of human epigenetic toxicities. Transgenerational toxicity is a concern but has not been well-studied.
3. Certain human disorders like Rett syndrome are caused by aberrant epigenetic regulation. Environmental stress can also cause heritable ep
EngenuitySC's Science Cafe - March with Dr. Patrick WosterEngenuitySC
This document discusses epigenetic modulation through inhibition of histone demethylases like LSD1. It summarizes that:
1) Polyamino(bis)guanidines and polyaminobiguanides can inhibit the histone demethylase LSD1 in vitro and in human colon cancer cells.
2) These inhibitors are non-competitive inhibitors of LSD1 and promote increased histone H3 lysine 4 dimethylation.
3) One inhibitor, verlindamycin (compound 2d), re-expresses tumor suppressor genes silenced in cancer cells and reduces tumor growth in mouse models of human colon cancer, especially in combination with 5-azacytidine.
Genetics differences affect drug metabolismfaysalahmed35
Genetics variation is a term used to describe the variation in the DNA sequence in each of our genomes. Individuals of a species have a similar characteristic but they are rarely identical, the difference between them called genetics variation.
Pharmacogenomic of TPMT which affected to plasma level of thiopurine drugsNat Nafz
This document outlines a presentation on thiopurine drugs including azathioprine, 6-mercaptopurine, and 6-thioguanine. It discusses their metabolism, mechanisms of action, adverse drug reactions, and importance of testing for thiopurine S-methyltransferase (TPMT) polymorphisms. TPMT activity affects levels of active drug metabolites and risk of toxicity. Genotype correlates with but does not perfectly predict phenotype. The presentation emphasizes dose adjustment based on TPMT levels and close monitoring to improve outcomes with thiopurine treatment.
This document summarizes a seminar on pharmacogenomics presented by Mr. Madhan Mohan Elsani. Pharmacogenomics is the study of how genes influence individual responses to drugs. Understanding genetic variations between individuals can help explain differences in drug efficacy and risk of adverse reactions. Single nucleotide polymorphisms (SNPs) are variations in DNA sequences that can impact how the body processes and metabolizes drugs. Pharmacogenomic testing can help optimize drug selection and dosing for individual patients based on their genetic makeup. This could improve drug safety and reduce adverse reactions.
MDM2 promotes the ubiquitination and degradation of FOXO transcription factors. The study found that MDM2 binds directly to FOXO1 and FOXO3A, promoting their ubiquitination and proteasome-mediated degradation. This degradation was dependent on FOXO phosphorylation by AKT and the E3 ligase activity of MDM2. Furthermore, activation of p53 led to increased MDM2 levels and degradation of endogenous FOXO3A. Therefore, MDM2 acts as an E3 ubiquitin ligase downstream of p53 to regulate FOXO protein stability.
Moxifloxacin is a broad-spectrum fluoroquinolone antibiotic. It works by inhibiting bacterial topoisomerase enzymes. It shows in vitro activity against Mycobacterium tuberculosis and other mycobacteria, with an MIC90 of 0.5 mg/mL against M. tuberculosis H37Rv. Animal studies found moxifloxacin to be as effective as or better than isoniazid at reducing M. tuberculosis counts in the spleen when used in combination with rifampin and pyrazinamide. Human trials also found moxifloxacin to have early bactericidal activity comparable to isoniazid against M. tuberculosis. Moxifloxacin has good oral bioavailability and
This document lists publications by István Kertész and others related to radiochemistry and peptide chemistry. It includes 20 journal articles published between 1996-2015 on topics like developing radiotracers for PET imaging, synthesizing opioid peptides and radiolabeling compounds. The publications involve developing new radiotracers and peptide ligands for imaging and characterizing receptors in the brain and tumors.
New And Emerging Therapies For Rheumatoid ArthritisApollo Hospitals
Rheumatoid Arthritis (RA) is a common rheumatological disorder. Many drugs including Anti TNF agents have been used for the treatment of this condition. The result hitherto, have been excellent, but shortcomings and the absence of complete remissions even in Anti TNF treated patients, makes the trial of newer agents, targeted to novel pathophysiologic molecules, all the more important and urgent. New insights in the pathogens of RA and three new biologics for RA have been discussed.
This document summarizes a study investigating the role of Set1-mediated histone H3 lysine 4 (H3K4) methylation in Saccharomyces cerevisiae survival under histidine starvation conditions. The study found that mono-methylation of H3K4 by Set1 is advantageous for optimal growth under these stressful conditions. New Set1 mutant strains, including ones capable of only mono-methylation or hyper methylation, were constructed to further examine the role of H3K4 methylation levels.
AXL kinase is a receptor tyrosine kinase which works using signal cascade mechanism and has essential use in anticancer activity of some drugs having AXL inhibition as thein mechanism of action
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...CrimsonpublishersCancer
One of the fundamental characteristic of tumor cell is to maintain the telomere length for continues progressive growth and survival. For the same, tumor cell has elevated levels of telomerase enzyme[1]. Telomerase is an unusual enzyme that acts on parts of chromosomes known as telomeres. Telomerase is a ribonucleoprotein and expressed in approximately 85% of different human cancers[2]. There is strong evidence for the existence of an important relationship between telomeres, telomerase and cancer [3]. Normal human cells progressively lose telomeres with each cell division until a few short telomeres become uncapped leading to a growth arrest, known as replicative aging. This phenomenon is totally absent in the cancer and cancer cells are adapted to have higher levels of telomerase enzyme which results in uncontrolled cell division. Attempts have also been made to develop telomere length-and telomerase-based diagnostic tools and anticancer therapeutics [4].
This clinical trial assessed the safety and immunogenicity of a polyvalent WT1 peptide vaccine in patients with acute myeloid leukemia (AML) in complete remission. Nine evaluable patients received six vaccinations over 12 weeks with four WT1 peptides plus adjuvants. WT1-specific T-cell responses were detected in seven of eight patients by assays such as ELISPOT and tetramer staining. The vaccine was found to be safely administered and induced immune responses against WT1. Further studies are needed to establish the role of vaccination as postremission therapy for AML.
1) The document summarizes research into combining AR and NOTCH inhibitors to treat ERG-positive prostate cancer. It finds that dual inhibition more strongly reduces cell survival, motility, invasion, and epithelial-mesenchymal transition compared to either inhibitor alone.
2) Experiments on VCaP prostate cancer cells show that combining GSI-1, a NOTCH inhibitor, with bicalutamide or enzalutamide, AR inhibitors, further decreases colony formation and HES-1 expression than single inhibitors.
3) Combination treatment also induces more expression of epithelial markers and reduces EMT compared to single inhibitors, suggesting it may better inhibit tumor progression. The study concludes dual inhibition results in greater anti
The document describes the process of filming a music video performance. The band members set up equipment like drums, amps, and instruments at the home of one of the members, who also directed. Filming took most of the day, with the director capturing various angles of the performance from 6-7 takes. Shots included close-ups of band members as well as wider aerial views. Additional footage was captured of band members noticing the protagonist outside to link the performance scenes to the overall story of the video.
60mm System Compact, 3-pole, 360A
Advantages of the system:
- compact control and distribution
- number of components is kept to a minimum
- many 60Classic components can be used here as well
This document describes research to develop new treatments for human African trypanosomiasis (HAT) by optimizing inhibitors of Trypanosoma brucei N-myristoyltransferase (TbNMT). The initial lead compound 1 showed potent activity against TbNMT but poor brain penetration, limiting its efficacy in the later central nervous system stage of HAT. The researchers modified compound 1 to improve blood-brain barrier permeability and selectivity against human NMTs. Key modifications included reducing the compound's polar surface area, replacing the central aromatic ring with a flexible linker, and capping the sulfonamide group. This led to the discovery of compound 40, which demonstrated partial efficacy in a mouse model
This document summarizes a study evaluating the toxicity and efficacy of novel targeted polymalic acid conjugate nanoparticles for treating triple-negative breast cancer. The nanoparticles were designed to target the epidermal growth factor receptor and laminin-411, a tumor vascular protein. In vitro and in vivo assays were conducted to evaluate the biocompatibility and toxicity of the polymalic acid platform and nanoparticle conjugates at low and high doses, as well as their efficacy in reducing tumor growth in mouse models over multiple treatment regimens. Blood analysis after intravenous administration in mice found no side effects, supporting the safety and potential of these nanoparticles for future cancer treatment in patients.
This document discusses immunotherapy strategies for metastatic renal cell carcinoma (RCC), including cytokines like interleukin-2 (IL-2) and interferon-α (IFN-α). It finds that high-dose IL-2 produces durable responses in a small percentage of selected patients, while IFN-α provides a modest survival benefit. Combining cytokines with targeted therapies may improve outcomes compared to cytokine monotherapy. Biomarkers like carbonic anhydrase IX expression and histologic subtype may help predict which patients are most likely to benefit from IL-2 therapy. Ongoing research aims to better select patients for IL-2 and explore combination therapies and novel immunotherapies to optimize treatment of metastatic RCC.
Novel 1,3,4-Thiadiazole Linked Amide Derivatives of Pteridone: Synthesis and ...Ratnakaram Venkata Nadh
Cancer is a second leading cause of death after heart attack, in developing as well as undeveloped
countries. It is caused by unregulated growth and metastasis of the abnormal cancer cells.
Cancer can be cured by radiation, immunotherapy and chemotherapy, among them; chemotherapy is a
good treatment for cancer, in which chemotherapeutic drug is used. The anticancer activity of newly
synthesized compounds (13a-j) was carried out on four different types of human cancer cell lines like
MCF-7 (breast), A549 (lung), Colo-205 (colon) and A2780 (ovarian) by the MTT method, and compared
to etoposide used as a positive control. Among them, compound 13g with electron-withdrawing
(3,5-dinitro) group, exhibited more promising activity in all cell lines (MCF-7 = 0.10±0.076 μM, A549
= 0.17±0.039 μM, Colo-205= 0.13±0.022 μM and A2780 = 0.87±0.027μM). This compound may act
as lead drug in cancer chemotherapy. In future, this compound can be examined for clinical studies.
MED12 controls the response to multiple cancer drugs through regulation of TG...Anirudh Prahallad
This study used an RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex, as a determinant of response to ALK and EGFR inhibitors in lung cancer cell lines. The study found that suppressing MED12 expression resulted in resistance to these targeted therapies. MED12 was found to negatively regulate TGF-β receptor signaling through physical interaction, and its suppression activated TGF-β signaling. Activation of TGF-β signaling led to MEK/ERK pathway activation, which conferred resistance to MEK, BRAF, and other cancer drugs. Loss of MED12 also induced an EMT-like phenotype associated with chemotherapy resistance in other cancer types. Inhibiting TGF-β receptor signaling
This document discusses epigenetically mediated toxicity and provides three key points:
1. Epigenetic modulation represents an intricate intersection of pharmacology, toxicology, and genotoxicity. It involves complex and reversible modifications to DNA and histones that can be influenced by environmental and therapeutic factors.
2. Toxicities associated with epigenetic modulation include effects on reproductive, hematopoietic, and developmental systems. However, there is no unique pattern of human epigenetic toxicities. Transgenerational toxicity is a concern but has not been well-studied.
3. Certain human disorders like Rett syndrome are caused by aberrant epigenetic regulation. Environmental stress can also cause heritable ep
EngenuitySC's Science Cafe - March with Dr. Patrick WosterEngenuitySC
This document discusses epigenetic modulation through inhibition of histone demethylases like LSD1. It summarizes that:
1) Polyamino(bis)guanidines and polyaminobiguanides can inhibit the histone demethylase LSD1 in vitro and in human colon cancer cells.
2) These inhibitors are non-competitive inhibitors of LSD1 and promote increased histone H3 lysine 4 dimethylation.
3) One inhibitor, verlindamycin (compound 2d), re-expresses tumor suppressor genes silenced in cancer cells and reduces tumor growth in mouse models of human colon cancer, especially in combination with 5-azacytidine.
Genetics differences affect drug metabolismfaysalahmed35
Genetics variation is a term used to describe the variation in the DNA sequence in each of our genomes. Individuals of a species have a similar characteristic but they are rarely identical, the difference between them called genetics variation.
Pharmacogenomic of TPMT which affected to plasma level of thiopurine drugsNat Nafz
This document outlines a presentation on thiopurine drugs including azathioprine, 6-mercaptopurine, and 6-thioguanine. It discusses their metabolism, mechanisms of action, adverse drug reactions, and importance of testing for thiopurine S-methyltransferase (TPMT) polymorphisms. TPMT activity affects levels of active drug metabolites and risk of toxicity. Genotype correlates with but does not perfectly predict phenotype. The presentation emphasizes dose adjustment based on TPMT levels and close monitoring to improve outcomes with thiopurine treatment.
This document summarizes a seminar on pharmacogenomics presented by Mr. Madhan Mohan Elsani. Pharmacogenomics is the study of how genes influence individual responses to drugs. Understanding genetic variations between individuals can help explain differences in drug efficacy and risk of adverse reactions. Single nucleotide polymorphisms (SNPs) are variations in DNA sequences that can impact how the body processes and metabolizes drugs. Pharmacogenomic testing can help optimize drug selection and dosing for individual patients based on their genetic makeup. This could improve drug safety and reduce adverse reactions.
MDM2 promotes the ubiquitination and degradation of FOXO transcription factors. The study found that MDM2 binds directly to FOXO1 and FOXO3A, promoting their ubiquitination and proteasome-mediated degradation. This degradation was dependent on FOXO phosphorylation by AKT and the E3 ligase activity of MDM2. Furthermore, activation of p53 led to increased MDM2 levels and degradation of endogenous FOXO3A. Therefore, MDM2 acts as an E3 ubiquitin ligase downstream of p53 to regulate FOXO protein stability.
Moxifloxacin is a broad-spectrum fluoroquinolone antibiotic. It works by inhibiting bacterial topoisomerase enzymes. It shows in vitro activity against Mycobacterium tuberculosis and other mycobacteria, with an MIC90 of 0.5 mg/mL against M. tuberculosis H37Rv. Animal studies found moxifloxacin to be as effective as or better than isoniazid at reducing M. tuberculosis counts in the spleen when used in combination with rifampin and pyrazinamide. Human trials also found moxifloxacin to have early bactericidal activity comparable to isoniazid against M. tuberculosis. Moxifloxacin has good oral bioavailability and
This document lists publications by István Kertész and others related to radiochemistry and peptide chemistry. It includes 20 journal articles published between 1996-2015 on topics like developing radiotracers for PET imaging, synthesizing opioid peptides and radiolabeling compounds. The publications involve developing new radiotracers and peptide ligands for imaging and characterizing receptors in the brain and tumors.
New And Emerging Therapies For Rheumatoid ArthritisApollo Hospitals
Rheumatoid Arthritis (RA) is a common rheumatological disorder. Many drugs including Anti TNF agents have been used for the treatment of this condition. The result hitherto, have been excellent, but shortcomings and the absence of complete remissions even in Anti TNF treated patients, makes the trial of newer agents, targeted to novel pathophysiologic molecules, all the more important and urgent. New insights in the pathogens of RA and three new biologics for RA have been discussed.
This document summarizes a study investigating the role of Set1-mediated histone H3 lysine 4 (H3K4) methylation in Saccharomyces cerevisiae survival under histidine starvation conditions. The study found that mono-methylation of H3K4 by Set1 is advantageous for optimal growth under these stressful conditions. New Set1 mutant strains, including ones capable of only mono-methylation or hyper methylation, were constructed to further examine the role of H3K4 methylation levels.
AXL kinase is a receptor tyrosine kinase which works using signal cascade mechanism and has essential use in anticancer activity of some drugs having AXL inhibition as thein mechanism of action
Targeting Telomerase and Topoisomerase-II by Natural Moieties: An Anti-Cancer...CrimsonpublishersCancer
One of the fundamental characteristic of tumor cell is to maintain the telomere length for continues progressive growth and survival. For the same, tumor cell has elevated levels of telomerase enzyme[1]. Telomerase is an unusual enzyme that acts on parts of chromosomes known as telomeres. Telomerase is a ribonucleoprotein and expressed in approximately 85% of different human cancers[2]. There is strong evidence for the existence of an important relationship between telomeres, telomerase and cancer [3]. Normal human cells progressively lose telomeres with each cell division until a few short telomeres become uncapped leading to a growth arrest, known as replicative aging. This phenomenon is totally absent in the cancer and cancer cells are adapted to have higher levels of telomerase enzyme which results in uncontrolled cell division. Attempts have also been made to develop telomere length-and telomerase-based diagnostic tools and anticancer therapeutics [4].
This clinical trial assessed the safety and immunogenicity of a polyvalent WT1 peptide vaccine in patients with acute myeloid leukemia (AML) in complete remission. Nine evaluable patients received six vaccinations over 12 weeks with four WT1 peptides plus adjuvants. WT1-specific T-cell responses were detected in seven of eight patients by assays such as ELISPOT and tetramer staining. The vaccine was found to be safely administered and induced immune responses against WT1. Further studies are needed to establish the role of vaccination as postremission therapy for AML.
1) The document summarizes research into combining AR and NOTCH inhibitors to treat ERG-positive prostate cancer. It finds that dual inhibition more strongly reduces cell survival, motility, invasion, and epithelial-mesenchymal transition compared to either inhibitor alone.
2) Experiments on VCaP prostate cancer cells show that combining GSI-1, a NOTCH inhibitor, with bicalutamide or enzalutamide, AR inhibitors, further decreases colony formation and HES-1 expression than single inhibitors.
3) Combination treatment also induces more expression of epithelial markers and reduces EMT compared to single inhibitors, suggesting it may better inhibit tumor progression. The study concludes dual inhibition results in greater anti
The document describes the process of filming a music video performance. The band members set up equipment like drums, amps, and instruments at the home of one of the members, who also directed. Filming took most of the day, with the director capturing various angles of the performance from 6-7 takes. Shots included close-ups of band members as well as wider aerial views. Additional footage was captured of band members noticing the protagonist outside to link the performance scenes to the overall story of the video.
60mm System Compact, 3-pole, 360A
Advantages of the system:
- compact control and distribution
- number of components is kept to a minimum
- many 60Classic components can be used here as well
The document discusses the evolution of labor modality towards freelancing. It notes that advances in technology allow work to be accomplished with less cost and worry, giving companies an advantage by saving money. Many employees are now leaving traditional jobs to become freelancers, allowing them to work more flexibly from their own time and space on multiple projects with quick payment. Freelancers can also choose their own projects and work hours without the stress of an office environment. Freelance websites like Team Creed provide access to thousands of qualified candidates in many fields immediately without lengthy interviews.
Bioschemas presentation at ECCB 2016, The HagueNiall Beard
Bioschemas is an open community initiative that aims to improve data interoperability in the life sciences. It does so by encouraging life scientists to use schema.org mark-up, so that their websites and services contain consistently structured information. This makes it easier to discover, collate and analyse distributed data. The main outcome of Bioschemas is a collection of specifications that provide guidelines to facilitate a more consistent adoption of schema.org mark-up within the life sciences.
This document provides information on the structure and projects of JSC "Lithuanian Railways", the largest transportation and logistics company in Lithuania. It discusses the company's directorates and subsidiaries, key metrics like revenues and passengers/freight carried, and infrastructure projects completed from 2007-2013 and planned from 2014-2020. Specifically, it focuses on the implementation of the Rail Baltica project, providing details on the stages of design, construction, and coordination involved in developing the rail line from Poland/Lithuania to Kaunas.
Introduction to Management - Meaning, Nature, Scope, Levels of ManagementSumit Sharaf
Introduction & Definition of Management
Components of Management
Features of Management
Functions of Management
Level of Management
Management and Administration
Management as Profession
Significance of Management from the point of view of Modern Business Operations.
The document provides case studies of LED lighting installations by Ledlights4you. It describes issues with existing fluorescent lighting at various office and industrial sites, the LED solutions provided by Ledlights4you using Epistar or Samsung LEDs, and the successful results including higher light levels, energy savings of 70-80%, and zero maintenance requirements compared to fluorescent lighting.
Este documento describe diferentes plataformas y herramientas para crear y compartir videos en línea. Explica que YouTube permite a los usuarios subir y compartir una variedad de videos, PowToon es un software que permite crear presentaciones animadas, Wideo es una plataforma para crear y editar videos animados utilizada por agencias de marketing, y Moovly permite crear contenido animado e infografías interactivas para publicar en redes sociales.
Science Behind The News: TAP(Triaminopyrimidine) discovered as a promising dr...Kiran Shaw
In a path breaking discovery, Scientists from Bengaluru and across the world have discovered triaminopyrimidine (TAP) as a promising drug candidate for malaria that kills the parasite rapidly over a long duration.This article published by Nature on the 31st of March dwells into the science behind this drug discovery.
The document describes a study that evaluated the effects of administering a mixture of 11 amino acids to patients with chronic heart failure over 3 months. The study found that amino acid supplementation significantly improved exercise tolerance as measured by increased peak VO2 and VO2 at anaerobic threshold on cardiopulmonary stress tests, as well as increased 6-minute walk test distances. However, it did not significantly change patients' quality of life scores. The study suggests amino acid supplementation may improve some measures of functional capacity in patients with chronic heart failure.
This curriculum vitae summarizes Robert B. Abel's education and professional experience. He has a Ph.D. in Statistics from Ohio State University and over 25 years of experience as a statistical consultant and biostatistician for pharmaceutical and biotech companies. His work has involved providing statistical support for clinical trials and product development across various therapeutic areas. He has authored over 30 publications and presentations related to biostatistics and clinical research.
This document lists posters presented at various conferences from 1994 to 2010 related to gene expression analysis of precision cut human liver slices, biomarkers for adverse drug reactions, screening of selective estrogen receptor modulators, and development of luciferase-based reporter assays in HepG2 cells. Many posters were presented by researchers including Elferink, Schoonen, Westerink, and others on topics such as toxicogenomics, phase I/II enzyme characterization, and toxico-metabolonomics.
Among patients with heart failure with preserved ejection fraction (HFPEF), a randomized clinical trial found that 24 weeks of treatment with the phosphodiesterase-5 inhibitor sildenafil, compared to placebo, did not significantly improve exercise capacity as measured by peak oxygen consumption or clinical status. Median changes in peak oxygen consumption and 6-minute walk distance were not significantly different between the sildenafil and placebo groups. The mean clinical status rank score, a composite of time to death or hospitalization and quality of life, was also not significantly different between groups at 24 weeks. Adverse events occurred in similar proportions of patients in both groups.
This research paper examines the ability of the drug nelfinavir to overcome multidrug resistance in MCF-7/Dox breast cancer cells. The study finds that multiple exposures to physiologically achievable concentrations of nelfinavir can significantly decrease the doxorubicin IC50 in MCF-7/Dox cells by inhibiting P-glycoprotein expression and function, suppressing AKT signaling pathways, and inducing endoplasmic reticulum stress pathways. In mouse models carrying MCF-7/Dox tumor xenografts, combination treatment with nelfinavir and doxorubicin decreased tumor growth more than either drug alone. The results suggest that nelfinavir can overcome multiple drug resistance
The document summarizes the discovery and development of the drug Gefitinib (Iressa), which was the first EGFR tyrosine kinase inhibitor developed for the treatment of non-small cell lung cancer. It describes how screening of compounds led to the selection of anilinoquinazolines as the lead series. Structure-activity studies aided the development of ZD1839 (Gefitinib), which showed good selectivity for EGFR kinase inhibition. Clinical trials demonstrated Gefitinib's ability to improve progression-free survival in NSCLC patients, leading to its FDA approval in 2003.
The comparison between effects of free curcumin and curcumin loaded PLGA-PEG ...Innspub Net
lung cancer is the most common cancer in men still now. Telomerase is responsible for cancerous cells immortality and is a suitable target for cancer therapy. TRF1 is a modulator for telomerase activity. It is necessary to find more efficient and safer anticancer drugs. Curcumin is a natural polyphenol which has many anticancer effects but it has hydrophobic structure and low solubility in water. PLGA-PEG nanoparticles was used to comprise effects of free curcumin and curcumin loaded PLGAPEG on telomerase and TRF1 expressions in lung cancer cell line. 1H NMR, FT-IR and SEM confirmed PLGA-PEG structure and curcumin loading on it.Then, cytotoxic effects of free curcumin and curcumin loaded PLGA-PEG determined by MTT assay. mRNA expression levels of hTERT and TRF1 was determined by Real-time PCR. MTT assay data analysis indicated that curcumin cytotoxicity is dose and time-dependent. Curcumin loaded nanoparticles showed IC50 values in lower concentration in comparison to free curcumin. Curcumin loaded PLGA-PEG decreased hTERT expression and increased TRF1 expression more than pure curcumin. Our study demonstrates curcumin loaded PLGA-PEG promises a natural and efficient system for
anticancer drug delivery to fight lung cancer. Get the full articles at: http://www.innspub.net/volume-4-number-10-may-2014/
This oral presentation made during ESMO 2016 highlight novel targets and drugs developed for patients with advanced neuroendocrine tumors. This includes targeted agents aiming probing cell signaling in tumor microenvironment and immune responses. Genetic alterations on major anti-oncogenes are reported in the perspective of pathway activations. Combinations using VEGFR, mTOR, Somatostatin receptors inhibitors with novel strategies and immunotherapy are also suggested. This presentation focuses mainly on gastrointestinal neuroendocrine tumors but may also be of interest for those involved in the care of patients with thoracic neuroendocrine tumors.
Mackenzie Cottrell, PharmD
Assistant Professor
Co-Director of the UNC CFAR Clinical Pharmacology and Analytical Chemistry Core
Division of Pharmacotherapy and Experimental Therapeutics
University of North Carolina at Chapel Hill
This document describes a study evaluating the toxicity and efficacy of targeted polymalic acid conjugates for treating triple-negative breast cancer. Polymalic acid nanoparticles were designed to target the epidermal growth factor receptor and laminin proteins, and were conjugated with antibodies and oligonucleotides. In vitro and in vivo experiments in mouse models evaluated the biocompatibility and toxicity of the nanoparticles and conjugates at low and high doses, as well as their efficacy in reducing tumor growth over multiple treatment regimens. Blood analysis found the dual-action conjugate highly effective at treating triple-negative breast cancer without side effects.
A common rejection module (CRM) for acute rejection across multiple organsKevin Jaglinski
This document summarizes a study that identified a common rejection module (CRM) of genes that are overexpressed during acute rejection across multiple solid organ transplants (heart, kidney, liver, lung). Through meta-analysis of gene expression data from transplant biopsies, the study identified 11 genes that comprise the CRM. Validation in independent cohorts showed the CRM genes can diagnose acute rejection with high accuracy. The CRM genes also correlated with the extent of graft injury and predicted future injury. Based on known drug mechanisms, the study explored using FDA-approved drugs atorvastatin and dasatinib to target specific CRM genes, reducing graft-infiltrating cells and extending graft survival in a mouse model of cardiac transplant rejection
An observational clinical study on the effectiveness of the aqueous leaf extr...Alexander Decker
This study evaluated the effectiveness of an aqueous leaf extract of Lippia multiflora in reducing blood pressure in 28 hypertensive patients over 4 weeks. Participants prepared an infusion from 30g of dried leaves boiled in water, taken twice daily. Results showed a significant decline in both systolic and diastolic blood pressure, with mean reductions of 11.6 mmHg and 6.43 mmHg respectively. The extract demonstrated potential as an antihypertensive agent through properties like diuresis, smooth muscle relaxation, and lipid lowering effects. Further research is warranted to explore higher dosages or modified formulations.
Wing Lam is a research scientist at Yale University specializing in herbal medicine and cancer pharmacology. He has over 15 years of experience identifying active compounds from herbs to treat diseases like cancer, metabolic disorders, and viral infections. Some of his accomplishments include developing the herbal formulation PHY906 to reduce chemotherapy side effects and enhance cancer treatment, identifying compounds that activate Wnt signaling for tissue regeneration, and developing nucleoside analogs for cancer and viral infections. He has published over 30 papers in peer-reviewed journals and presented at international conferences on topics related to herbal medicine and cancer chemotherapy.
The document discusses generics and biosimilars in medical practice. It makes three main points:
1. While generics can reduce costs significantly, some generics have shown to be therapeutically nonequivalent to the innovator drug and can impact treatment outcomes. Strict bioequivalence standards are needed.
2. Biosimilars offer opportunities to expand access but present unique challenges due to their complexity. They are not simple copies and may have unintended immunogenic consequences without rigorous clinical testing.
3. Regulatory standards for approving generics and biosimilars in Colombia are less stringent than other countries, which could put patients at risk if efficacy and safety are not adequately demonstrated. Tighter standards are needed
This document discusses the identification of TACC1, NOV, and PTTG1 as potential new biomarkers associated with endocrine therapy resistance in breast cancer. The study used two cell models, MVLN/CL6.7 and VP229/VP267, that were selected for resistance to tamoxifen and acquired cross-resistance to fulvestrant. 26 candidate genes were examined by RTQ-PCR and 8 genes were found overexpressed in breast cancer patient samples that relapsed after tamoxifen treatment. TACC1, NOV, and PTTG1 were identified as independent prognostic markers associated with shorter relapse-free survival. Aberrant mRNA and protein levels of these 3 genes were also observed in
This document discusses the identification of TACC1, NOV, and PTTG1 as potential new biomarkers associated with endocrine therapy resistance in breast cancer. Two cell models, MVLN/CL6.7 and VP229/VP267, were used that had acquired resistance to tamoxifen and cross-resistance to fulvestrant. 26 candidate genes related to cell proliferation, transformation, apoptosis and DNA repair were examined in these cell lines using RTQ-PCR. Genes with deregulated expression were further analyzed in samples from 48 ER-positive breast cancer patients, half of whom relapsed after tamoxifen treatment. TACC1, NOV, and PTTG1 were found to be over
This document discusses the identification of TACC1, NOV, and PTTG1 as potential new biomarkers associated with endocrine therapy resistance in breast cancer. Two cell models, MVLN/CL6.7 and VP229/VP267, were used that had acquired resistance to tamoxifen and cross-resistance to fulvestrant. 26 candidate genes related to cell proliferation, transformation, apoptosis and DNA repair were examined in these cell lines using RTQ-PCR. Genes with deregulated expression were further analyzed in samples from 48 ER-positive breast cancer patients, half of whom relapsed after tamoxifen treatment. Aberrant mRNA and protein levels of TACC1, NOV, and PTT
Impacts of genomics, proteomics, and metabolomics pptGloria Okenze
This document discusses the impacts of genomics, proteomics, and metabolomics technologies, known collectively as "omics" technologies, on medicinal plant research. It describes how each type of omics technology works - genomics analyzes genetic information, proteomics studies proteins, and metabolomics qualitatively and quantitatively analyzes low molecular weight metabolites. These technologies allow comprehensive analysis of biological systems and open new perspectives for ethnobotanical and medicinal plant research. The document outlines specific applications of omics technologies, such as botanical identification, characterization of active components, standardization of herbal extracts, and drug metabolism studies. It also notes some disadvantages like expense and labor intensiveness.
Impacts of genomics, proteomics, and metabolomics ppt
Publications G LEFEVRE
1. September 2015
DR. GILBERT LEFEVRE - PUBLICATIONS
1. Josso N, Vigier B, Picard JY, Lefèvre G, Tran D. Anti-Müllerian Hormone. The fifth International Meeting of
the International Society of Differentiation, Boulder, Collorado, USA, 3-7 August 1987.
2. Legeai L, Lefèvre G, Vigier B, Picard JY, Josso N. A monoclonal antibody against human testicular Anti-
Müllerian Hormone. Am J Reprod Immunol Microbiol 1988, 18: 39-42.
3. Lefèvre G, Tran D, Hœbeke J, Josso N. Anti-idiotype antibodies to a monoclonal antibody raised against Anti-
Müllerian Hormone exhibit anti-Müllerian biological activity. Mol Cell Endocrinol 1989, 62: 125-133.
4. Cardot JM, Lefèvre G, Godbillon J. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous
administration. J Pharm Biopharm 1994, 22: 147-156.
5. Zoldhelyi P, Janssens S, Lefèvre G, Van de Werf F. Were plasma hirudin levels in the GUSTO-2A trial higher
than expected from pharmacokinetics studies in volunteers with stable coronary disease ? American College of
Cardiology, 44th
Annual Scientific Session, April 1995.
6. Zoldhelyi P, Janssens S, Lefèvre G, Collen D, Van de Werf F. Effects of heparin and hirudin (CGP 39393) on
thrombin generation during thrombolysis for acute myocardial infarction. Circulation 1995, Vol 92 (Suppl I),
No 8.
7. Zoldhelyi P, Janssens S, Lefèvre G, Collen D, Van de Werf F. Accelerated thrombin generation during
conjunctive treatment of myocardial infarction with t-PA and r-hirudin. XVth
Congress of the International
Society on Thrombosis and Haemostasis. Jerusalem, Israel, June 11-16, 1995.
8. Zoldhelyi P, Janssens S, Lefèvre G, Van de Werf F. Plasma hirudin and aPTT levels in acute patients of the
GUSTO-2A trial compared with hirudin levels and aPTT in volunteers with stable coronary disease. Eur Heart
J 1995, 16 (Suppl): 177.
9. Kinoshita T, Kawasugi K, Yamanaka H, Sagawa T, Koyama Y, Hama H, Hamauzu T, Ogushi J, Nishimura M,
Kuyama Y, Matsuda J, Kamakura M, Miyake K, Nagase M, Yasuda K, Kazama M, Yamanaka M, Lefèvre G.
Clinical evaluation of recombinant hirudin, CGP 39 393. Phase I study: single and multiple dose administration
in healthy volunteers. J Clinical Therapeutic and Medicines [Article in Japanese] 1995, 6: 1143-1175.
10. Gygax D, Botta L, Ehrat M, Graf P, Lefèvre G, Oroszlan P, Pfister C. Immuno and other approaches in
pharmacokinetics. 11th
Bioanalytical Forum, University of Surrey, Guildford, UK and 4th
International
Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Vienna, Austria, 1995. In Methodological
Surveys in Bioanalysis of Drugs, Vol 24. Biofluid assay for peptide-related and other drugs; Ed. E. Reid, H. M.
Hill; I. D. Wilson, 1996, pp 11-19.
11. Lefèvre G, Duval M, Botta L, Godbillon J. Direct microtitre plate radioimmunoassay of savoxepine in
unextracted plasma. J Immunoassay 1996, 17(1): 29-46.
12. Gygax D, Botta L, Ehrat M, Graf P, Lefèvre G, Oroszlan P, Pfister C. Immunoassays in monitoring
biotechnological drugs. Ther Drug Monit 1996, 18 (4): 405-409.
13. Godbillon J, Cardot JM, Lecaillon JB, Lefèvre G, Sioufi A. Bioequivalence assessment: a pharmaceutical
industry perspective. Eur J Drug Metab Pharmacokinet 1996, 21(2): 153-158.
14. Müller P, Botta L, Lefèvre G, Ezzet F. Pharmacokinetics of a new oestradiol matrix patch in healthy
postmenopausal volunteers and symptomatic women. World Congress of Gynecology, November 1996,
Sydney, Australia.
15. Lefèvre G, Duval M, Gauron S, Piraino A, Morgan J, Palmisano M, Brookman L, Rolan P, Godbillon J, Close
P. The effects of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin (™REVASC).
Sixth European Congress of Biopharmaceutics and Pharmacokinetics, Athens, Greece, April 22-24th
, 1996. Eur
J Drug Metab Pharmacokinet 1996, (Suppl) No 263: 89.
16. Amin DM, Mant TGK, Walker SM, Kerry R, Lloyd P, Lefèvre G, Close P. Effect of a 15-minute infusion of
DDAVP on the pharmacokinetics and pharmacodynamics of ™REVASC during a four-hour intravenous
infusion in healthy male volunteers. Thromb Haemostas 1997, 77: 127-132.
17. Colussi D, Parisot C, Brunner L, Rossolino M, Lefèvre G. Protein binding in plasma of valsartan, a new
angiotensin II receptor antagonist. J Clin Pharmacol 1997, 37(3): 214-221.
2. September 2015
18. Lefèvre G, Duval M, Gauron S, Brookman L, Rolan P, Morris T, Piraino A, Morgan J, Palmisano M, Close P.
The effects of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol
Ther 1997, 62: 50-59.
19. Colussi D, Parisot C, Lefèvre G. Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme
inhibitor. J Clin Pharmacol 1998, 38: 727-735.
20. Thomsen M, Lefèvre G, Ezzet F, Bindschedler M. Co-artemether: pharmacokinetic profile of a combined anti-
malaria compound treatment. 2nd
European Congress on Tropical Medicine, Liverpool, UK, 14-18th
September
1998, Abstr. No. P31.
21. Colussi D, Parisot C, Lefèvre G. Binding of iralukast to serum proteins and erythrocytes: measurements using
ultrafiltration and an erythrocyte partitioning method. Eur J Pharm Sci 1998, 7: 167-173.
22. Parisot C, Colussi D, Lefèvre G. Co-artemether: protein binding of artemether and lumefantrine. 7th
European
Congress of Biopharmaceutics and Pharmacokinetics (ECBP) and 5th
Congress of the European Federation of
Pharmaceutical Sciences (EUFEPS), Jerusalem, Israel, 25-30 April 1999. Eur J Pharm Sci 1999, 8(2): xxvii,
Abstr. No. 110.
23. Colussi D, Parisot C, Legay F, Lefèvre G. Binding of artemether and lumefantrine to plasma proteins and
erythrocytes. Eur J Pharm Sci 1999, 9: 9-16.
24. Lefèvre G, Thomsen M. Clinical pharmacokinetics of artemether and lumefantrine (Riamet
). Clin Drug Invest
1999, 18(6): 467-480.
25. Lefèvre G, Gauron S. Automated quantitative determination of the new renin inhibitor CGP 60536 by high-
performance liquid chromatography. J Chromatogr 2000, 738(1): 129-136.
26. Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen M. Pharmacokinetic interaction trial
between co-artemether and mefloquine. Eur J Pharm Sci 2000, 10(2): 141-151.
27. Lefèvre G, Duval M, Poncin A. Direct micro-radioimmunoassay of the new renin inhibitor CGP60536. J
Immunoassay 2000, 21(1): 65-84.
28. Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M. Cardiac effects of co-artemether
(artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin
Pharmacol 2000, 56: 375-381.
29. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krodsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R.
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug resistant
Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001, 64(5,6): 247-256.
30. Bindschedler M, Lefèvre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials co-
artemether and halofantrine in healthy participants. Am J Trop Med Hyg 2002, 66(3): 295-300.
31. Lefèvre G. No evidence of cardiotoxicity of co-artemether in comparison to halofantrine (oral communication).
The Royal College of Physicians of London, 11 St
Andrew Place, Regent Park, London, UK. 25-April-2002.
32. Lefèvre G, Carpenter P, Souppart C, Schmidli H, Martin JM, Lane A, Ward C, Amakye D. Interaction trial
between artemether-lumefantrine (Riamet®
) and quinine in healthy subjects. J Clin Pharmacol 2002, 42(10):
1147-1158.
33. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and
electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®
) with concomitant
administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 2002, 54: 485-492.
34. Lefèvre G. Antipaludiques et Cardiotoxicité – Profil de tolérance de Coartem®
et interactions médicamenteuses
(communication orale). Universités Africaines Coeur-Paludisme, 16-17th
Novembre 2002, Paris, France.
35. Lefèvre G. Pharmacokinetic and cardiosafety data on an artemisinin combination (oral communication). 8th
Conference of the International Society of Travel Medicine (CISTM8), 9th
May 2003, New York, USA.
36. Lefèvre G et al. 8th
Conference of the International Society of Travel Medicine (CISTM8), 7-11th
May 2003,
New York, USA.
Presentation of 6 posters on Coartem®
/Riamet®
:
36. Pharmacokinetics of artemether-lumefantrine (Coartem®
/Riamet®
), including the effect of food (Lefèvre et al.)
37. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand
(Lefèvre et al.)
38. Interaction trial between artemether-lumefantrine (Riamet®
) and quinine in healthy subjects (Lefèvre et al.)
3. September 2015
39. Pharmacokinetic interaction trial and study on cardiac effects between co-artemether and Mefloquine (Lefèvre et al.)
40. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®
) with concomitant administration of
ketoconazole in healthy subjects (Lefèvre et al.)
41. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants (Bindschedler et al.)
42. Lefèvre G, Makanga M, Falade C, Ibarra de Palacios P, Denouël J, Schmidli H. Pharmacokinetics of the 6-dose
regimen of co-artemether in African infants and children with acute, uncomplicated falciparum malaria. 52nd
Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), 3-7 December 2003,
Philadelphia, PA, USA.
43. Makanga M, Fallade C, Premji Z, Ibarra de Palacios P, Stockmeyer M, Lefèvre G. Efficacy, safety and
pharmacokinetics of a co-artemether (artemether 20 mg, lumefantrine 120 mg) 6-dose regimen in african
infants and children with acute, uncomplicated Plasmodium falciparum malaria (oral communication). Africa
European Conference on Travel Medicine (AECTM), 8-11th
February 2004, Cape Town, South Africa.
44. Lefèvre G. Clinical pharmacokinetics and cardiosafety (QTc) profile of Coartem®
. Advisory Board Meeting.
10-11 March 2005, Dakar, Senegal.
45. Lefèvre G, Sędek S, Huang A, Saltzman M, Rosenberg M, Kiese B, Fordham P. Pharmacokinetics of a
transdermal patch formulation of rivastigmine in healthy volunteers: relative effects of body site application. J
Clin Pharmacol 2007, 47: 471-478.
46. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch.
Neurology 2007, 69: S10-S13.
47. Abdulla S, Sagara I, Borrmann S, Nahum A, Bassat Q, Hamel M, Ogutu B, Björkman A, Andriano K, Cousin
M, Lefèvre G, Ubben D. Efficacy and safety of a new dispersible tablet formulation of artemether-lumefantrine
in pediatric patients with acute uncomplicated Plasmodium falciparum malaria – Randomized, investigator-
blinded, multicenter comparison with the crushed tablet. 56nd
Annual Meeting of the American Society of
Tropical Medicine and Hygiene (ASTMH), 4-8th
November 2007, Philadelphia, PA, USA.
48. Mercier F, Lefèvre G, Huang A, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided
by a transdermal patch versus capsules. Curr Med Res Opin 2007, 23: 3199-3204.
49. Mercier F, Lefèvre G, Huang A, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided
by a transdermal patch versus capsules (poster). 10th
International Hong Kong / Springfield Pan-Asian
Symposium on Advances in Alzheimer Therapy, 28 February-1 March 2008, Hong Kong.
50. Lefèvre G, Sędek G, Jhee S, Leibowitz MT, Huang A, Enz A, Maton S, Ereshefsky L, Lopez P, Ho YY, Sagan
C, Appel-Dingemanse S. Pharmacokinetics and bioavailability of the novel daily rivastigmine transdermal
patch compared with twice-daily capsules in patients with mild-to-moderate Alzheimer’s disease. Clin
Pharmacol Ther 2008, 83: 106-114.
51. Lefèvre G, Pommier F, Sędek G, Allison M, Huang A, Kiese B, Ho YY, Appel-Dingemanse S.
Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral
solution in healthy elderly subjects. J Clin Pharmacol 2008, 48: 246-252.
52. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard GD, Andriano K,
Lefèvre G, Ibarra de Palacios P, Genton B. Treatment of acute uncomplicated falciparum malaria with
artemether-lumefantrine in non-immune populations: a safety, efficacy and pharmacokinetic study. Am J Trop
Med Hyg 2008, 78(2): 241-247.
53. Shua-Haim J, Smith S, Picard F, Sedek S, Athalye S, Pommier F, Lefèvre G. Steady-state pharmacokinetics of
rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of
memantine. Clin Drug Invest 2008, 28(6): 361-374.
54. Borrmann S, Sallas W, Marrast AC, Lefèvre G, Kern S. Impact of African diet components on exposure to
lumefantrine in infants and children receiving artemether-lumefantrine (Coartem) for uncomplicated malaria.
ICTM 2008, XVIIth
International Congress for Tropical Medicine and Malaria, Sept 29-Oct 3, 2008, Jeju
Island, Korea.
55. Borrmann S, Djimé A, Abdulla S, Lefèvre G, Andriano K. Pharmacokinetic-pharmacodynamic features of
artemether-lumefantrine administered as dispersible tablet compared to the crushed commercial tablet in
African children with P. falciparum malaria. ICTM 2008, XVIIth
International Congress for Tropical Medicine
and Malaria, Sept 29-Oct 3, 2008, Jeju Island, Korea.
4. September 2015
56. Lefèvre G, Abdulla S, Lyimo J, Agyemang A, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M, Rivière
GJ, Séchaud R. Early development of the new artemether-lumefantrine dispersible tablet: Palatability and
pharmacokinetics in healthy subjects. ASTMH 2008, 57th
Annual Meeting of the American Society of Tropical
Medicine and Hygiene, 7/11-Dec-2008, New Orleans, LA, USA.
57. Borrmann S, Sallas W, Marrast AC, Lefèvre G, Kern S. Exposure to lumefantrine in infants receiving
artemether-lumefantrine (Coartem) for uncomplicated malaria: impact of African diet components. ASTMH
2008, 57th
Annual Meeting of the American Society of Tropical Medicine and Hygiene, 7-11-Dec-2008, New
Orleans, LA, USA.
58. Djimdé A, Borrmann S, Abdulla S, Lefèvre G, Andriano K. Pharmacokinetic and pharmacodynamic
characteristics of a new dispersible tablet formulation of artemether-lumefantrine compared to the crushed
commercial tablet in African children with P. falciparum malaria. ASTMH 2008, 57th
Annual Meeting of the
American Society of Tropical Medicine and Hygiene, 7/11-Dec-2008, New Orleans, LA, USA.
59. Abdulla S, Sagara I, Borrmann S, D’Alessandro U, Gonzales R, Hamel M, Ogutu B, Martensson A, Lyimo J,
Maiga H, Sasi P, Nahum A, Bassat Q, Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M,
Lefèvre G, Ubben D, Premji Z. Efficacy and safety of artemether-lumefantrine dispersible tablet in African
infants and children with uncomplicated malaria: a randomized, investigator-blinded, multicentre comparison
with the crushed commercial tablet. Lancet 2008, 372: 1819-1827.
60. Lefèvre G, Büche M, Sędek G, Maton S, Enz A, Lorch U, Sagan C, Appel-Dingemanse S. Similar rivastigmine
pharmacokinetics and pharmacodynamics in Japanese and White healthy participants following the application
of novel rivastigmine patch. J Clin Pharmacol 2009, 49: 430-443.
61. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of
Alzheimer’s disease: a review. Int J Clin Pract 2009, 63(5): 799-805.
62. Djimdé A and Lefèvre G. Understanding the pharmacokinetics of Coartem®
. Malar J 2009, 8 (Suppl 1): S4.
63. Juma E, Sallas WM, Lyimo J, Marrast AC, Lefèvre G, Djimdé A. Exposure to lumefantrine in infants and
children receiving artemether-lumefantrine for uncomplicated malaria: impact of African diet components.
PMA and KPA Conferences 2009.
64. Djimdé A, Sallas WM, Lyimo J, Marrast AC, Lefèvre G, Borrmann S. Exposure to lumefantrine in infants and
children receiving artemether-lumefantrine for uncomplicated malaria: impact of African diet components. 5th
Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference, 2-6th
Nov 2009, Nairobi, Kenya.
65. Abdulla S, Lefèvre G, Lyimo J, Agyemang A, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M, Rivière
GJ, Séchaud R. Early development of the new artemether-lumefantrine dispersible tablet: palatability and
pharmacokinetics. 5th
Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference, 2-6th
Nov
2009, Nairobi, Kenya.
66. Borrmann S, Sallas WM, Machevo S, Gonzáles R, Björkman A, Mårtensson A, Hamel M, Juma E, Ogutu B,
Djimdé A, D’Alessandro U, Marrast AC, Lefèvre G, Kern SE. The effect of food consumption on lumefantrine
bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem®
)
for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2010, 15(4): 434-441.
67. Borrmann S, Sallas WM, Machevo S, Gonzáles R, Björkman A, Mårtensson A, Hamel M, Juma E, Ogutu B,
Djimdé A, D’Alessandro U, Marrast AC, Lefèvre G, Kern SE. The effect of food consumption on lumefantrine
bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem®
)
for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2010, 15(4): 434-341.
68. Abdulla S, Amuri B, Kabanywanyi AM, Ubben D, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M,
Séchaud R, Kaiser G, Lefèvre G. Early clinical development of artemether-lumefantrine dispersible tablet:
palatability of three flavours and bioavailability in healthy subjects. Malar J 2010, 9: 253-261.
69. Lefèvre G, Klingelhöfer L, Mollenhauer B, Kassubek J, Ebersbach G, Tenenbaum N. Pharmacokinetics of
rivastigmine patch (Exelon) in patients with Parkinson’s disease dementia. The 10th
International Conference
on Alzheimer’s & Parkinson’s diseases. Barcelona, Spain, March 9-13, 2011.
70. Lefèvre G, Marrast AC, Grüninger H. Novartis malaria initiative: best practice example of pharmaceutical
industry’s engagement in the fight against malaria. Ann NY Acad Sci 2011, 1222: 19-29.
71. Eckermann G, Lefèvre G. Cytochrome P-450 enzymes and their influence on the efficacy and safety of
cholinesterase inhibitor treatment for Alzheimer’s disease. Abstract accepted for the 164th
Annual Meeting of
The American Psychiatric Association (APA), May 14-18, 2011, Honolulu, Hawaii.
5. September 2015
72. Djimdé A, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, Lefèvre G, Borrmann S. Pharmacokinetic
and pharmacodynamic characteristics of a new pediatric formulation (dispersible tablet) of artemether-
lumefantrine in African children with uncomplicated malaria. Antimicrob Agents Chemother 2011, 55(9):
3994-3999.
73. Meremikwu M, Alao MJ, Gbadoé AD, Tshefu A, Lefèvre G, Walter V, Cousin M, Hamed K, Ogutu B.
Evaluation of the efficacy, safety and PK of artemether-lumefantrine dispersible tablet in the treatment of acute
uncomplicated Plasmodium falciparum malaria in infants weighing <5 kg. 7th European Congress on Tropical
Medicine & International Health, Oct 3-6, 2011, Barcelona, Spain.
74. Bassat Q, Menéndez C, Machevo S, Nahum A, Lyimo J, Maiga H, Märtensson A, Bashraheil M, Ouma P,
Walter V, Nwaiwu O, Kipkeu C, Lefèvre G, Ogutu B. Artemether-lumefantrine (Coartem) body weight ranges
are associated with similar efficacy and safety in African infants and children with uncomplicated falciparum
malaria. Malar J 2011, 10(1): 369.
75. Carrasquilla G, Barón C, Monsell EM, Cousin M, Walter V, Lefèvre G, Sander O, and Fisher LM.
Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-
lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg
2012, 86(1): 75-83.
76. Hamed K, Meremiku M, Alao MJ, Gbadoé, Tshefu A, Lefèvre G, Walter V, Cousin M, Ogutu B. Evaluation of
the efficacity, safety and pharmacokinetics of artemether-lumefantrine dispersible tablet in the treatment of
acute uncomplicated Plasmodium falciparum malaria in infants weighing <5 kg. Abstract at the VIII
International Congress for Tropical Medicine and Malaria (ICTMM) and XLVIII Congress of the Brazilian
Society for Tropical Medicine. Rio de Janeiro, Brazil, 2012.
77. Jain JP, Lakshminarayana SB, Lefèvre G, Sivasubramanian R, Blasco F, Sunkara G. Differences in the
pharmacokinetics of currently approved antimalarial drugs in uncomplicated malaria patients compared to
healthy subjects. Malar J 2012, 11 S1 P118.
78. Lefèvre G, Bhad P, Jain JP, Stein D, Kalluri S, Hardike D, Kaiser G. The novel 80/480 mg tablet formulation
of artemether-lumefantrine (Coartem®
) is bioequivalent to a dose of four individual standard tablets in healthy
volunteers. Abstract/poster at 61st
Annual Meeting of the American Society of tropical Medicine and Hygiene
(ASTMH), Atlanta, Georgia, USA, 2012.
79. Diagana T, Leong J, Lefèvre G. Discovery and early development of novel antimalarial drugs for the treatment
pf P. falciparum and P. viva malaria. In: Keystone meeting Drug Discovery for Protozoan Parasites (J1), 15-20
January 2012, Santa Fe, USA.
80. Lefèvre G, Bhad P, Jain JP, Kalluri S, Cheng Y, Stein DS. Evaluation of two novel tablet formulations of
artemether-lumefantrine (Coartem®
) for bioequivalence in a randomized, open-label, two-period study. Malar
J 2013, 12: 312-322.
81. Lamorde M, Byakika-Kibwika P, Mayito J, Nabukeera L, Ryan M, Hanpithakpong W, Lefèvre G, Back D,
Khoo S, Merry C. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-
based tuberculosis treatment. AIDS 2013, 27(6): 961-965.
82. White N, Nosten F, Pukrittayakamee S, Jittmala P, Pyae Phyo A, Rueangweerayut R, Diagana T, Li R,
Magnusson B, Lefèvre G, Jain JP, Leong J. Rapid clearance of parasitemia by the novel spiroindolone
KAE609 in a phase 2 open-label study of adults with acute, uncomplicated Plasmodium falciparum or vivax
malaria mono-infection. 62nd
Annual Meeting of the American Society of Tropical Medicine and Hygiene
(ASTMH), Washington DC, USA, 2013.
83. White N, Pukrittayakamee S, Pyae Phyo A, Rueangweerayut R, Nosten F, Jittmala P, Jain JP, Lefèvre G, Li R,
Magnusson B, Diagana T, Leong FJ. Spiroindolone KAE609 for falciparum and vivax malaria. NEJM 2014,
371(5): 403-410.
84. Leong FJ, Li R, Jain JP, Lefèvre G, Magnusson B, Diagana T, Pertel P. A first-in-human randomized, double-
blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone
KAE609 (Cipargamin) to assess its safety, tolerability and pharmacokinetics in healthy adult volunteers.
Antimicrob Agents Chemother 2014, 58(10): 1-6.
85. Leong FJ, Li R, Jain JP, Lefèvre G, Magnusson B, Diagana T, Pertel P. A first-in-human randomized, double-
blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone
KAE609 (cipargamin), to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers.
Challenges in Malaria Research Conference 2014 (Sept), University of Oxford, UK.
6. September 2015
86. Stein DS, Jain JP, Lickliter J, Kangas M, Machineni S, Griffin P, Lefèvre G. A phase 1 study evaluation of the
pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 (cipargamin) and
piperaquine. Challenges in Malaria Research Conference 2014 (Sept), University of Oxford, UK.
87. Stein DS, Jain JP, Lickliter J, Kangas M, Machineni S, Griffin P, Lefèvre G. A phase 1 evaluation of the
pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 and Piperaquine (PPQ). 63rd
Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) 2014 (Nov), New
Orleans, USA.
88. Tiono AB, Tinto H, Alao MJ, Meremikwu M, Tshefu A, Ogutu B, Ouedraogo A, Lingani M, Cousin M,
Lefèvre G, Jain JP, Duparc S, Hamed K. Increased systemic exposures of artemether and dihydroartemisinin in
infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine
(Coartem®
). Malar J 2015, 14: 157-167.
89. Stein D, Jain JP, Kangas M, Lefèvre G, Machineni S, Griffin P, and Lickliter J. Open-Label, single-dose,
parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609
(cipargamin) and piperaquine. Antimicrob Agents Chemother 2015, 59(6): 3493-500.
90. Lefèvre G, Callegari F, Xiong Y, Nox S. Absence of effect of renal impairment on rivastigmine
pharmacokinetics in patients with Alzheimer ’s Disease. 1st
Congress of the European Academy of Neurology.
Berlin, Germany, June 20-23 2015.
91. Lefèvre G, Callegari F, Xiong Y. Absence of effect of renal impairment on rivastigmine pharmacokinetics in
patients with Alzheimer’s Disease. The 2015 Alzheimer’s Disease Congress, London, UK, June 23-25 2015.
92. Jain JP, Ganesan S, Lefèvre G, Sunkara G. Estimation of amount of artemether and lumefantrine excreted
through breast milk. 9th
European Congress on Tropical Medicine and International Health (ECTMIH 2015),
Basle, Switzerland, 6-13 September 2015.
93. Jain JP, Ganesan S, Lefèvre G, Sunkara G. Estimation of amount of artemether and lumefantrine excreted
through breast milk. 64th
Annual Meeting of the American Society of Tropical Medicine and Hygiene
(ASTMH), Philadelphia, PA, USA, 25-29 October 2015.
94. WWARN Lumefantrine PK/PD Study Group. Artemether-lumefantrine treatment of uncomplicated
Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations
and therapeutic response using individual patient data. BMC Mediciene 1015, 13:227-246.
95. Lefèvre G, Callegari F, Gsteiger S, Xiong Y. No effect of renal impairment on rivastigmine pharmacokinetics
in patients with Alzheimer’s Disease. Final version under submission.
96. Han Y, Li L, Lefèvre G, Chen Y, Zeng S, Ufer M, Hockey HU, Zhao R. Pharmacokinetics of the rivastigmine
transdermal patch in healthy Chinese subjects after single and multiple administrations. To be submitted.